NEXT GENERATION OF EXTRACORPOREAL ALBUMIN DETOXIFICATION (ECAD) IMPROVES SURROGATE SURVIVAL BIOMARKERS WHEN COMPARED WITH MARS IN A RANDOMIZED TRIAL

NEXT GENERATION OF EXTRACORPOREAL ALBUMIN DETOXIFICATION (ECAD) IMPROVES SURROGATE SURVIVAL BIOMARKERS WHEN COMPARED WITH MARS IN A RANDOMIZED TRIAL

Objectives: Meta analysis have concluded that Extracorporeal Albumin Detoxification (ECAD) using MARSTM provides a short term survival benefit. In order to further improve survival, the next generation of ECAD adsorbents, („HepalbinTM") was investigated in a clinical trial. Methods: Subjects wi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of artificial organs 2023-07, Vol.46 (7), p.409
Hauptverfasser: Sponholz, C, Kortgen, A, Bauer, M, Wilms, C, Schmidt, H, Dollinger, M, Backhus, J, Koball, S, Hinz, M, Mitzner, S, Klammt, S, Stange, J
Format: Artikel
Sprache:eng
Schlagworte:
Albumin
Albumins
Bile acids
Bilirubin
Binding
Bioassays
Biomarkers
Detoxification
Effectiveness
Granulocytes
Hepatotoxicity
Leukocytes (granulocytic)
Phagocytosis
Reduction
Survival
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Objectives: Meta analysis have concluded that Extracorporeal Albumin Detoxification (ECAD) using MARSTM provides a short term survival benefit. In order to further improve survival, the next generation of ECAD adsorbents, („HepalbinTM") was investigated in a clinical trial. Methods: Subjects with an indication for ECAD were randomized to receive either MARSTM first and HepalbinTM second or vice versa. Serum samples investigated for reduction of bilirubin, bile acids and improvement of albumin binding function. Clinical parameters, hepatocyte and granulocyte function were measured. Results: Total bilirubin was reduced from 360±165 to 285±131 umol/l by 21% by HepalbinTM and from 354±178 to 287±149 umol/l by 19% by MARSTM (p
ISSN:0391-3988
1724-6040